Holen Sie sich die Stockscreener-App
1.35
1.46%
-0.02
Handel nachbörslich:
1.35
Schlusskurs vom Vortag:
$1.37
Offen:
$1.37
24-Stunden-Volumen:
75,424
Relative Volume:
0.16
Marktkapitalisierung:
$3.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.26M
KGV:
-0.0252
EPS:
-53.609
Netto-Cashflow:
$-12.17M
1W Leistung:
+12.50%
1M Leistung:
-25.00%
6M Leistung:
-88.38%
1J Leistung:
-98.15%
1-Tages-Spanne:
$1.33
$1.39
1-Wochen-Bereich:
$1.20
$1.40
52-Wochen-Spanne:
$1.10
$81.77
Gri Bio Inc Stock (GRI) Company Profile
Firmenname
Gri Bio Inc
Sektor
Branche
Telefon
(619) 400-1171
Adresse
2223 AVENIDA DE LA PLAYA, LA JOLLA
Vergleichen Sie GRI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.35 | 2.57M | 0 | -8.26M | -12.17M | -53.61 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-09 | Eingeleitet | H.C. Wainwright | Buy |
Gri Bio Inc Aktie (GRI) Neueste Nachrichten
GRI Bio (NASDAQ:GRI) Price Target Cut to $34.00 by Analysts at Ascendiant Capital Markets - Defense World
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Sto - GuruFocus
GRI Bio: Ascendiant Capital Lowers Price Target to $34 | GRI Stock News - GuruFocus
GRI Bio (NASDAQ:GRI) Trading Down 4% – Here’s Why - Defense World
GRI Bio expands at-the-market offering capacity By Investing.com - Investing.com Nigeria
GRI Bio Expands Share Offering Agreement - TipRanks
GRI Bio expands at-the-market offering capacity - Investing.com
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary Fibrosis Treatment | GRI Stock News - GuruFocus
GRI Bio Reports Positive Preclinical Data For GRI-0621 - Nasdaq
GRI Bio (GRI) Shows Promising Preclinical Results in Pulmonary F - GuruFocus
GRI Bio IncPhase 2A Study Results For GRI-0621 Expected In Q2 2025 - marketscreener.com
GRI Bio reports progress in pulmonary fibrosis treatment By Investing.com - Investing.com India
GRI Bio reports progress in pulmonary fibrosis treatment - Investing.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results - Yahoo Finance
GRI Bio Advances in IPF Treatment with Promising Trial Results - TipRanks
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
GRI Bio CEO Reveals Next Steps in NKT Cell Therapy Development at Virtual Investor Series - Stock Titan
GRI Bio meets interim clinical trial enrollment goal for IPF therapy - Pulmonary Fibrosis News
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - The Manila Times
GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan
GRI Bio reports positive early trial data for IPF treatment By Investing.com - Investing.com India
GRI: Q1 Financial Report Highlights and Future Prospects | GRI S - GuruFocus
GRI Bio reports positive early trial data for IPF treatment - Investing.com
GRI: Q1 Financial Report Highlights and Future Prospects | GRI Stock News - GuruFocus
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - The Manila Times
GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis Treatment - Nasdaq
GRI Bio, Inc. SEC 10-Q Report - TradingView
GRI Bio Reports First Quarter 2025 Financial Results and - GlobeNewswire
GRI Bio reports positive interim biomarker data in IPF study By Investing.com - Investing.com Nigeria
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend - GlobeNewswire
GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect Of GRI-0621 - marketscreener.com
GRI Bio reports positive interim biomarker data in IPF study - Investing.com
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
GRI Bio Continues To Drive Enrollment In Ongoing Phase 2A Study Of GRI-0621 In Idiopathic Pulmonary Fibrosis - marketscreener.com
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ('IPF”) - The Manila Times
GRI Bio (GRI) to Release Earnings on Friday - Defense World
GRI Bio Inc (GRI) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
FY2025 Earnings Forecast for GRI Bio Issued By HC Wainwright - Defense World
GRI Bio appoints Withum as new accounting firm By Investing.com - Investing.com Canada
GRI Bio Announces Abstract Selected for Poster Discussion - GlobeNewswire
Major Scientific Breakthrough: GRI Bio's Novel Pulmonary Fibrosis Treatment Shows Promise - Stock Titan
GRI Bio appoints Withum as new accounting firm - Investing.com Australia
GRI Bio (NASDAQ:GRI) Given Buy Rating at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on GRI Bio stock, $10 target - Investing.com Australia
H.C. Wainwright maintains Buy on GRI Bio stock, $10 target By Investing.com - Investing.com South Africa
GRI stock touches 52-week low at $1.2 amid market fluctuations - Investing.com
Finanzdaten der Gri Bio Inc-Aktie (GRI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):